目的探究达格列净对2型糖尿病(T2DM)合并高血压病患者血压变异性(BPV)和左心室质量指数(LVMI)的作用。方法选择2021年8月至2022年8月丽水市中心医院收治的T2DM合并高血压病患者为研究对象,分别给予常规治疗(对照组)和达格列净治疗(试验...目的探究达格列净对2型糖尿病(T2DM)合并高血压病患者血压变异性(BPV)和左心室质量指数(LVMI)的作用。方法选择2021年8月至2022年8月丽水市中心医院收治的T2DM合并高血压病患者为研究对象,分别给予常规治疗(对照组)和达格列净治疗(试验组)。比较两组患者的BPV指标、LVMI、血糖水平的变化及不良反应发生率。结果研究共纳入94例T2DM合并高血压病患者,试验组和对照组各47例。两组T2DM合并高血压病患者的24 h舒张压均数(DBP)、24 h收缩压均数(SBP)、24 h收缩压标准差(SSD)、24 h舒张压标准差(DSD)、空腹血糖(FBG)、2 h血糖(PG)、糖化血红蛋白(HbA1c)、体重指数(BMI)及LVMI显著降低(P<0.05),且试验组的24 h SBP、24 h DBP、24 h SSD、24 h DSD、FPG、2 h PG、HbA1c、BMI及LVMI均低于对照组(P<0.05)。试验组与对照组的不良反应总发生率分别为10.64%和4.26%,差异无统计学意义(P>0.05)。结论达格列净可降低T2DM合并高血压病患者LVMI,改善患者BPV及血糖水平,且安全性较好。展开更多
Ischemic brain injury is a major disease which threatens human health and safety.(3, 5, 6-trimethylpyrazin-2-yl) methyl 3-methoxy-4-[(3, 5, 6-trimethylpyrazin-2-yl) methoxy] benzoate(VA-T), a newly discovered lead com...Ischemic brain injury is a major disease which threatens human health and safety.(3, 5, 6-trimethylpyrazin-2-yl) methyl 3-methoxy-4-[(3, 5, 6-trimethylpyrazin-2-yl) methoxy] benzoate(VA-T), a newly discovered lead compound, is effective for the treatment of ischemic brain injury and its sequelae. But the poor solubility of VA-T leads to poor dissolution and limited clinical application. In order to improve the dissolution of VA-T, the pharmaceutical technology of solid dispersions was used in the present study. VA-T/ polyvinylpyrrolidone(PVP) solid dispersion was prepared by the solvent method. The dissolution studies were carried out and solid state characterization was evaluated by differential scanning calorimetry(DSC), infrared spectroscopy(IR), x-ray diffraction(XRD) and scanning electron microscopy(SEM). The dissolution rate of VA-T was significantly improved by solid dispersion compared to that of the pure drug and physical mixture. The results of DSC and XRD indicated that the VA-T solid dispersion was amorphous. The IR spectra showed the possible interaction between VA-T and PVP was the formulation of hydrogen bonding. The SEM analysis demonstrated that there was no VA-T crystal observed in the solid dispersions. The ideal drug-to-PVP ratio was 1 : 5. In conclusion, the solid dispersion technique can be successfully used for the improvement of the dissolution profile of VA-T.展开更多
文摘目的探究达格列净对2型糖尿病(T2DM)合并高血压病患者血压变异性(BPV)和左心室质量指数(LVMI)的作用。方法选择2021年8月至2022年8月丽水市中心医院收治的T2DM合并高血压病患者为研究对象,分别给予常规治疗(对照组)和达格列净治疗(试验组)。比较两组患者的BPV指标、LVMI、血糖水平的变化及不良反应发生率。结果研究共纳入94例T2DM合并高血压病患者,试验组和对照组各47例。两组T2DM合并高血压病患者的24 h舒张压均数(DBP)、24 h收缩压均数(SBP)、24 h收缩压标准差(SSD)、24 h舒张压标准差(DSD)、空腹血糖(FBG)、2 h血糖(PG)、糖化血红蛋白(HbA1c)、体重指数(BMI)及LVMI显著降低(P<0.05),且试验组的24 h SBP、24 h DBP、24 h SSD、24 h DSD、FPG、2 h PG、HbA1c、BMI及LVMI均低于对照组(P<0.05)。试验组与对照组的不良反应总发生率分别为10.64%和4.26%,差异无统计学意义(P>0.05)。结论达格列净可降低T2DM合并高血压病患者LVMI,改善患者BPV及血糖水平,且安全性较好。
基金supported by the Natural Science Foundation of Zhejiang Province,China(No.LY15H180005)the National Natural Science Foundation of China(No.81173466,81072415)
基金financially supported by National Natural Science Foundation of China(No.81173563)Ministry of National Science and Technology(China+2 种基金Nos.2012ZX09103201-0262009ZX09102-142)the Innovation Team of Beijing University of Chinese Medicine(No.2011-CXTD-13)
文摘Ischemic brain injury is a major disease which threatens human health and safety.(3, 5, 6-trimethylpyrazin-2-yl) methyl 3-methoxy-4-[(3, 5, 6-trimethylpyrazin-2-yl) methoxy] benzoate(VA-T), a newly discovered lead compound, is effective for the treatment of ischemic brain injury and its sequelae. But the poor solubility of VA-T leads to poor dissolution and limited clinical application. In order to improve the dissolution of VA-T, the pharmaceutical technology of solid dispersions was used in the present study. VA-T/ polyvinylpyrrolidone(PVP) solid dispersion was prepared by the solvent method. The dissolution studies were carried out and solid state characterization was evaluated by differential scanning calorimetry(DSC), infrared spectroscopy(IR), x-ray diffraction(XRD) and scanning electron microscopy(SEM). The dissolution rate of VA-T was significantly improved by solid dispersion compared to that of the pure drug and physical mixture. The results of DSC and XRD indicated that the VA-T solid dispersion was amorphous. The IR spectra showed the possible interaction between VA-T and PVP was the formulation of hydrogen bonding. The SEM analysis demonstrated that there was no VA-T crystal observed in the solid dispersions. The ideal drug-to-PVP ratio was 1 : 5. In conclusion, the solid dispersion technique can be successfully used for the improvement of the dissolution profile of VA-T.
